{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:08:14Z","timestamp":1784855294958,"version":"3.55.0"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Union within the framework of the EU4H Programme","award":["101084921"],"award-info":[{"award-number":["101084921"]}]},{"name":"European Union within the framework of the EU4H Programme","award":["101156495"],"award-info":[{"award-number":["101156495"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We describe herein the European Reference Network on Rare Endocrine Conditions clinical practice guideline on diagnosis and management of familial forms of hyperaldosteronism. The guideline panel consisted of 10 experts in primary aldosteronism, endocrine hypertension, paediatric endocrinology, and cardiology as well as a methodologist. A systematic literature search was conducted, and because of the rarity of the condition, most recommendations were based on expert opinion and small patient series. The guideline includes a brief description of the genetics and molecular pathophysiology associated with each condition, the patients to be screened, and how to screen. Diagnostic and treatment approaches for patients with genetically determined diagnosis are presented. The recommendations apply to patients with genetically proven familial hyperaldosteronism and not to families with more than one case of primary aldosteronism without demonstration of a responsible pathogenic variant.<\/jats:p>","DOI":"10.1093\/ejendo\/lvae041","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:39:03Z","timestamp":1712219943000},"page":"G1-G14","source":"Crossref","is-referenced-by-count":36,"title":["Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5480-1116","authenticated-orcid":false,"given":"Paolo","family":"Mulatero","sequence":"first","affiliation":[{"name":"Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino , 10126 Torino , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute I","family":"Scholl","sequence":"additional","affiliation":[{"name":"Center of Functional Genomics, Berlin Institute of Health at Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , 10115 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E","family":"Fardella","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Centro Traslacional de Endocrinolog\u00eda Universidad Cat\u00f3lica (CETREN-UC), Pontificia Universidad Cat\u00f3lica de Chile , 8330033 Santiago , Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Charmandari","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School , Athens 11527 , Greece"},{"name":"Division of Endocrinology and Metabolism, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens , Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Januszewicz","sequence":"additional","affiliation":[{"name":"Department of Hypertension, National Institute of Cardiology , 02-628 Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9875","authenticated-orcid":false,"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Department of Medicine 4, LMU University Hospital, LMU Munich , Munich D-80336 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso E","family":"Gomez-Sanchez","sequence":"additional","affiliation":[{"name":"Research Service, G. V. (Sonny) Montgomery VA Medical Center , Jackson, MS 39216 , United States"},{"name":"Department of Pharmacology and Toxicology, University of Mississippi Medical Center , Jackson, 39216 MS , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-8584","authenticated-orcid":false,"given":"Michael","family":"Stowasser","sequence":"additional","affiliation":[{"name":"Endocrine Hypertension Research Centre, University of Queensland Frazer Institute, Greenslopes and Princess Alexandra Hospitals , Brisbane, 4102 Queensland , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-7580","authenticated-orcid":false,"given":"Olaf M","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Departments of Clinical Epidemiology and Internal Medicine, Leiden University Medical Centre , 2311 Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"issue":"5","key":"2024042910113337200_lvae041-B1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024042910113337200_lvae041-B2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"issue":"4","key":"2024042910113337200_lvae041-B3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1152\/physrev.00026.2015","article-title":"Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney","volume":"96","author":"Stowasser","year":"2016","journal-title":"Physiol Rev"},{"issue":"6","key":"2024042910113337200_lvae041-B4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"9","key":"2024042910113337200_lvae041-B5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"2024042910113337200_lvae041-B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024042910113337200_lvae041-B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"issue":"10","key":"2024042910113337200_lvae041-B8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/HJH.0000000000002520","article-title":"Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"issue":"5","key":"2024042910113337200_lvae041-B9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/HYPERTENSIONAHA.121.16498","article-title":"Genetics of primary aldosteronism","volume":"79","author":"Scholl","year":"2022","journal-title":"Hypertension"},{"issue":"7","key":"2024042910113337200_lvae041-B10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1043-2760(03)00112-7","article-title":"Primary aldosteronism: from genesis to genetics","volume":"14","author":"Stowasser","year":"2003","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"2024042910113337200_lvae041-B11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.111.175083","article-title":"Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms)","volume":"58","author":"Mulatero","year":"2011","journal-title":"Hypertension"},{"issue":"3","key":"2024042910113337200_lvae041-B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0031-1299730","article-title":"The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience","volume":"44","author":"Pallauf","year":"2012","journal-title":"Horm Metab Res"},{"issue":"22","key":"2024042910113337200_lvae041-B13","first-page":"1109","article-title":"Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone","volume":"95","author":"Sutherland","year":"1966","journal-title":"Can Med Assoc J"},{"issue":"6357","key":"2024042910113337200_lvae041-B14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"issue":"1","key":"2024042910113337200_lvae041-B15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ng0992-66","article-title":"Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase","volume":"2","author":"Lifton","year":"1992","journal-title":"Nat Genet"},{"issue":"5","key":"2024042910113337200_lvae041-B16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/jcem-59-5-1022","article-title":"Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism","volume":"59","author":"Gomez-Sanchez","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024042910113337200_lvae041-B17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat Genet"},{"issue":"3","key":"2024042910113337200_lvae041-B18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","article-title":"A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism","volume":"50","author":"Fernandes-Rosa","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"2024042910113337200_lvae041-B19","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-019-13033-4","article-title":"Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation","volume":"10","author":"Schewe","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2024042910113337200_lvae041-B20","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/s41467-019-12113-9","article-title":"Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism","volume":"10","author":"G\u00f6ppner","year":"2019","journal-title":"Nat Commun"},{"issue":"6018","key":"2024042910113337200_lvae041-B21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"1","key":"2024042910113337200_lvae041-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JME-15-0324","article-title":"Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production","volume":"57","author":"Hattangady","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"2024042910113337200_lvae041-B23","doi-asserted-by":"crossref","first-page":"e06315","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"eLife"},{"key":"2024042910113337200_lvae041-B24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","article-title":"CACNA1H mutations are associated with different forms of primary aldosteronism","volume":"13","author":"Daniil","year":"2016","journal-title":"EBioMedicine"},{"issue":"8","key":"2024042910113337200_lvae041-B25","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1210\/en.2016-1170","article-title":"CACNA1H(M1549V) mutant calcium channel causes autonomous aldosterone production in HAC15 cells and is inhibited by mibefradil","volume":"157","author":"Reimer","year":"2016","journal-title":"Endocrinology"},{"issue":"17","key":"2024042910113337200_lvae041-B26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014876118","article-title":"Enhanced Ca2+ signaling, mild primary aldosteronism, and hypertension in a familial hyperaldosteronism mouse model (Cacna1hM1560V\/+)","volume":"118","author":"Seidel","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2024042910113337200_lvae041-B27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"2024042910113337200_lvae041-B28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","article-title":"A de novo CACNA1D missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia","volume":"14","author":"De Mingo Alemany","year":"2020","journal-title":"Channels (Austin)"},{"issue":"6","key":"2024042910113337200_lvae041-B29","doi-asserted-by":"crossref","first-page":"E900","DOI":"10.1210\/jc.2014-4167","article-title":"Primary aldosteronism and ARMC5 variants","volume":"100","author":"Zilbermint","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042910113337200_lvae041-B30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/jhh.2015.98","article-title":"ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions","volume":"30","author":"Mulatero","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"8","key":"2024042910113337200_lvae041-B31","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/HJH.0b013e3283028352","article-title":"Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families","volume":"26","author":"Sukor","year":"2008","journal-title":"J Hypertens"},{"issue":"1","key":"2024042910113337200_lvae041-B32","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1038\/s41467-022-32896-8","article-title":"Identification of risk loci for primary aldosteronism in genome-wide association studies","volume":"13","author":"Le Floch","year":"2022","journal-title":"Nat Commun"},{"issue":"12 Pt 2","key":"2024042910113337200_lvae041-B33","first-page":"1610","article-title":"Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I","volume":"13","author":"Stowasser","year":"1995","journal-title":"J Hypertens"},{"issue":"7","key":"2024042910113337200_lvae041-B34","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1210\/jcem.87.7.8647","article-title":"Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree","volume":"87","author":"Mulatero","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042910113337200_lvae041-B35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.jhh.1001636","article-title":"Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism","volume":"18","author":"Fallo","year":"2004","journal-title":"J Hum Hypertens"},{"issue":"5","key":"2024042910113337200_lvae041-B36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1042\/cs0880563","article-title":"Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression","volume":"88","author":"Jamieson","year":"1995","journal-title":"Clin Sci (Lond)"},{"issue":"1-2","key":"2024042910113337200_lvae041-B37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/07435809509030463","article-title":"Clinical, biochemical and genetic features of five extended kindred's with glucocorticoid-suppressible hyperaldosteronism","volume":"21","author":"Jamieson","year":"1995","journal-title":"Endocr Res"},{"issue":"4","key":"2024042910113337200_lvae041-B38","first-page":"255","article-title":"Dexamethasone-suppressible hyperaldosteronism: a large new kindred","volume":"3","author":"O\u2019Mahony","year":"1989","journal-title":"J Hum Hypertens"},{"issue":"10","key":"2024042910113337200_lvae041-B39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-116-10-813","article-title":"Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype","volume":"116","author":"Rich","year":"1992","journal-title":"Ann Intern Med"},{"issue":"5","key":"2024042910113337200_lvae041-B40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1067\/mpd.2001.112648","article-title":"Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood","volume":"138","author":"Dluhy","year":"2001","journal-title":"J Pediatr"},{"issue":"1 Pt 2","key":"2024042910113337200_lvae041-B41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/01.HYP.31.1.445","article-title":"Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism","volume":"31","author":"Litchfield","year":"1998","journal-title":"Hypertension"},{"issue":"6","key":"2024042910113337200_lvae041-B42","first-page":"2160","article-title":"Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance","volume":"85","author":"Stowasser","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024042910113337200_lvae041-B43","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","article-title":"A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism","volume":"93","author":"Geller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042910113337200_lvae041-B44","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1210\/jc.2014-3636","article-title":"A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue","volume":"100","author":"Monticone","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024042910113337200_lvae041-B45","doi-asserted-by":"crossref","first-page":"E1532","DOI":"10.1210\/jc.2012-1334","article-title":"A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension","volume":"97","author":"Charmandari","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042910113337200_lvae041-B46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/cimb44010010","article-title":"Familial hyperaldosteronism type 3 with a rapidly growing adrenal tumor: an in situ aldosterone imaging study","volume":"44","author":"Takizawa","year":"2021","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"2024042910113337200_lvae041-B47","doi-asserted-by":"crossref","first-page":"E1861","DOI":"10.1210\/jc.2013-2428","article-title":"A Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III","volume":"98","author":"Monticone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024042910113337200_lvae041-B48","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1073\/pnas.1121407109","article-title":"Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5","volume":"109","author":"Scholl","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2024042910113337200_lvae041-B49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.111.183996","article-title":"KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism","volume":"59","author":"Mulatero","year":"2012","journal-title":"Hypertension"},{"issue":"7","key":"2024042910113337200_lvae041-B50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00424-020-02418-w","article-title":"De novo CACNA1D Ca2+ channelopathies: clinical phenotypes and molecular mechanism","volume":"472","author":"Ortner","year":"2020","journal-title":"Pflugers Arch"},{"key":"2024042910113337200_lvae041-B51","doi-asserted-by":"crossref","first-page":"1131490","DOI":"10.3389\/fneur.2023.1131490","article-title":"Case report: clinical delineation of CACNA1D mutation: new cases and literature review","volume":"14","author":"Alzahrani","year":"2023","journal-title":"Front Neurol"},{"issue":"4","key":"2024042910113337200_lvae041-B52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2024042910113337200_lvae041-B53","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2024042910113337200_lvae041-B54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2024042910113337200_lvae041-B55","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"12 Pt 2","key":"2024042910113337200_lvae041-B56","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/00004872-199715120-00080","article-title":"Evidence for persistent dysfunction of wild-type aldosterone synthase gene in glucocorticoid-treated familial hyperaldosteronism type I","volume":"15","author":"Stowasser","year":"1997","journal-title":"J Hypertens"},{"issue":"1","key":"2024042910113337200_lvae041-B57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"2024042910113337200_lvae041-B58","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042910113337200_lvae041-B59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/HYPERTENSIONAHA.110.168740","article-title":"Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation","volume":"57","author":"Aglony","year":"2011","journal-title":"Hypertension"},{"issue":"9","key":"2024042910113337200_lvae041-B60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2024042910113337200_lvae041-B61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0031-1295460","article-title":"Factors affecting the aldosterone\/renin ratio","volume":"44","author":"Stowasser","year":"2012","journal-title":"Horm Metab Res"},{"key":"2024042910113337200_lvae041-B62","doi-asserted-by":"crossref","first-page":"116774","DOI":"10.1016\/j.jns.2020.116774","article-title":"Primary aldosteronism in young adults with acute stroke: prevalence and clinical characteristics","volume":"413","author":"Tang","year":"2020","journal-title":"J Neurol Sci"},{"issue":"4","key":"2024042910113337200_lvae041-B63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11906-019-0934-y","article-title":"Pathogenesis of familial hyperaldosteronism type II: new concepts involving anion channels","volume":"21","author":"Stowasser","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"2024042910113337200_lvae041-B64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2024042910113337200_lvae041-B65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"issue":"11","key":"2024042910113337200_lvae041-B66","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1210\/clinem\/dgac460","article-title":"Approach to the patient on antihypertensive therapy: screen for primary aldosteronism","volume":"107","author":"Mulatero","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024042910113337200_lvae041-B67","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/HJH.0000000000001571","article-title":"Aldosterone-to-renin ratio depends on age and sex in children attending a clinic for cardiovascular risk assessment","volume":"36","author":"Genovesi","year":"2018","journal-title":"J Hypertens"},{"key":"2024042910113337200_lvae041-B68","doi-asserted-by":"crossref","first-page":"8647026","DOI":"10.1155\/2018\/8647026","article-title":"Age-related cutoffs of plasma aldosterone\/renin concentration for primary aldosteronism screening","volume":"2018","author":"Ma","year":"2018","journal-title":"Int J Endocrinol"},{"issue":"3","key":"2024042910113337200_lvae041-B69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/HYPERTENSIONAHA.110.155135","article-title":"Aldosterone, plasma Renin activity, and aldosterone\/renin ratio in a normotensive healthy pediatric population","volume":"56","author":"Martinez-Aguayo","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"2024042910113337200_lvae041-B70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.111.180513","article-title":"A new presentation of the chimeric CYP11B1\/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern","volume":"59","author":"Carvajal","year":"2012","journal-title":"Hypertension"},{"issue":"3","key":"2024042910113337200_lvae041-B71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1440-1681.1987.tb00378.x","article-title":"Aldosterone regulation during saline infusion: usefulness of aldosterone\/cortisol ratio in the diagnosis of aldosterone-producing adenoma","volume":"14","author":"Hamlet","year":"1987","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"7","key":"2024042910113337200_lvae041-B72","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2006-0078","article-title":"Comparison of confirmatory tests for the diagnosis of primary aldosteronism","volume":"91","author":"Mulatero","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024042910113337200_lvae041-B73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.107.091827","article-title":"Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma","volume":"50","author":"Rossi","year":"2007","journal-title":"Hypertension"},{"issue":"1","key":"2024042910113337200_lvae041-B74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/HYPERTENSIONAHA.117.10197","article-title":"Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study","volume":"71","author":"Song","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"2024042910113337200_lvae041-B75","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1172\/JCI118279","article-title":"Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree","volume":"96","author":"Pascoe","year":"1995","journal-title":"J Clin Invest"},{"issue":"12","key":"2024042910113337200_lvae041-B76","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/jhh.2017.34","article-title":"Familial hyperaldosteronism type III","volume":"31","author":"Monticone","year":"2017","journal-title":"J Hum Hypertens."},{"issue":"11","key":"2024042910113337200_lvae041-B77","first-page":"3570","article-title":"Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism","volume":"82","author":"Litchfield","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024042910113337200_lvae041-B78","first-page":"3996","article-title":"Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol","volume":"83","author":"Mulatero","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024042910113337200_lvae041-B79","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1006\/bbrc.1995.1225","article-title":"A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension","volume":"207","author":"Jonsson","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2024042910113337200_lvae041-B80","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ecl.2011.01.012","article-title":"Glucocorticoid-remediable aldosteronism","volume":"40","author":"Halperin","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"2024042910113337200_lvae041-B81","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","article-title":"Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I","volume":"90","author":"Stowasser","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024042910113337200_lvae041-B82","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)","volume":"41","author":"Mancia Chairperson","year":"2023","journal-title":"J Hypertens"},{"issue":"15","key":"2024042910113337200_lvae041-B83","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jacc.2022.08.714","article-title":"Cardiac phenotypes in secondary hypertension: JACC state-of-the-art review","volume":"80","author":"Januszewicz","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2024042910113337200_lvae041-B84","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa159","article-title":"Low quality of reports on blood pressure in patients adrenalectomized for unilateral primary aldosteronism","volume":"105","author":"Lenders","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024042910113337200_lvae041-B85","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","article-title":"2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement","volume":"39","author":"Stergiou","year":"2021","journal-title":"J Hypertens"},{"issue":"2","key":"2024042910113337200_lvae041-B86","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1530\/JOE-14-0597","article-title":"An update on novel mechanisms of primary aldosteronism","volume":"224","author":"Zennaro","year":"2015","journal-title":"J Endocrinol"},{"issue":"13","key":"2024042910113337200_lvae041-B87","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1055\/s-0035-1565124","article-title":"Cardiovascular risk in primary hyperaldosteronism","volume":"47","author":"Prejbisz","year":"2015","journal-title":"Horm Metab Res"},{"issue":"2","key":"2024042910113337200_lvae041-B88","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"issue":"12","key":"2024042910113337200_lvae041-B89","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"issue":"6","key":"2024042910113337200_lvae041-B90","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"22","key":"2024042910113337200_lvae041-B91","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"2024042910113337200_lvae041-B92","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"issue":"5","key":"2024042910113337200_lvae041-B93","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"2024042910113337200_lvae041-B94","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"2024042910113337200_lvae041-B95","doi-asserted-by":"crossref","first-page":"H813","DOI":"10.1152\/ajpheart.00113.2003","article-title":"Aldosteronism: an immunostimulatory state precedes proinflammatory\/fibrogenic cardiac phenotype","volume":"285","author":"Gerling","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2024042910113337200_lvae041-B96","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","article-title":"Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury","volume":"37","author":"Fiebeler","year":"2001","journal-title":"Hypertension"},{"issue":"12","key":"2024042910113337200_lvae041-B97","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/nm.2506","article-title":"Oxidation of CaMKII determines the cardiotoxic effects of aldosterone","volume":"17","author":"He","year":"2011","journal-title":"Nat Med"},{"issue":"12","key":"2024042910113337200_lvae041-B98","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"issue":"8","key":"2024042910113337200_lvae041-B99","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"2024042910113337200_lvae041-B100","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1210\/jc.2011-0354","article-title":"Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study","volume":"96","author":"Pimenta","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024042910113337200_lvae041-B101","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/jhh.2010.102","article-title":"Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma","volume":"25","author":"Pimenta","year":"2011","journal-title":"J Hum Hypertens"},{"issue":"3","key":"2024042910113337200_lvae041-B102","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1210\/clinem\/dgz051","article-title":"Patients with primary aldosteronism respond to unilateral adrenalectomy with long-term reduction in salt intake","volume":"105","author":"Adolf","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024042910113337200_lvae041-B103","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/HYPERTENSIONAHA.120.16440","article-title":"Altered taste perception for sodium chloride in patients with primary aldosteronism: a prospective cohort study","volume":"77","author":"Adolf","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"2024042910113337200_lvae041-B104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/joim.13618","article-title":"Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: the salt CONNtrol trial","volume":"294","author":"Schneider","year":"2023","journal-title":"J Intern Med"},{"issue":"6","key":"2024042910113337200_lvae041-B105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41371-022-00690-0","article-title":"2022 world Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action","volume":"37","author":"Campbell","year":"2022","journal-title":"J Hum Hypertens"},{"issue":"9","key":"2024042910113337200_lvae041-B106","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jcem.85.9.6834","article-title":"Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension","volume":"85","author":"Stowasser","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024042910113337200_lvae041-B107","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-0760(01)00097-8","article-title":"Familial hyperaldosteronism","volume":"78","author":"Stowasser","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"2024042910113337200_lvae041-B108","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/HYPERTENSIONAHA.123.21054","article-title":"Systematic review of therapeutic agents and long-term outcomes of familial hyperaldosteronism type 1","volume":"80","author":"Tan","year":"2023","journal-title":"Hypertension"},{"issue":"2","key":"2024042910113337200_lvae041-B109","first-page":"650","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"2024042910113337200_lvae041-B110","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"2024042910113337200_lvae041-B111","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","article-title":"Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism","volume":"44","author":"Satoh","year":"2021","journal-title":"Hypertens Res"},{"issue":"5","key":"2024042910113337200_lvae041-B112","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2024042910113337200_lvae041-B113","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/bcp.15713","article-title":"CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers","volume":"89","author":"Mulatero","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"9231","key":"2024042910113337200_lvae041-B114","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(00)02624-6","article-title":"Dexamethasone-suppressible hypertension","volume":"356","author":"Stewart","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"2024042910113337200_lvae041-B115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.HYP.28.6.927","article-title":"Inherited forms of mineralocorticoid hypertension","volume":"28","author":"White","year":"1996","journal-title":"Hypertension"},{"issue":"25","key":"2024042910113337200_lvae041-B116","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199812173392507","article-title":"Primary aldosteronism","volume":"339","author":"Ganguly","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"2024042910113337200_lvae041-B117","first-page":"3670","article-title":"In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild-type genes","volume":"82","author":"Stowasser","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042910113337200_lvae041-B118","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"2024042910113337200_lvae041-B119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/heart.88.5.475","article-title":"Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure","volume":"88","author":"Farquharson","year":"2002","journal-title":"Heart"},{"issue":"7","key":"2024042910113337200_lvae041-B120","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jch.13567","article-title":"Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy","volume":"21","author":"Izzo","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"2024042910113337200_lvae041-B121","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"issue":"6","key":"2024042910113337200_lvae041-B122","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1507\/endocrj.EJ11-0406","article-title":"Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism","volume":"59","author":"Mussa","year":"2012","journal-title":"Endocr J"},{"issue":"1","key":"2024042910113337200_lvae041-B123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11154-022-09729-6","article-title":"Primary aldosteronism in pregnancy","volume":"24","author":"Forestiero","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2024042910113337200_lvae041-B124","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12020-021-02763-5","article-title":"A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy","volume":"74","author":"Sanga","year":"2021","journal-title":"Endocrine"},{"issue":"33","key":"2024042910113337200_lvae041-B125","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"2024042910113337200_lvae041-B126","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/01.HYP.35.2.668","article-title":"Glucocorticoid-remediable aldosteronism and pregnancy","volume":"35","author":"Wyckoff","year":"2000","journal-title":"Hypertension"},{"issue":"4","key":"2024042910113337200_lvae041-B127","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4158\/EP14512.RA","article-title":"Genetics of primary aldosteronism","volume":"21","author":"Vaidya","year":"2015","journal-title":"Endocr Pract"},{"issue":"2","key":"2024042910113337200_lvae041-B128","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000358197","article-title":"Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature","volume":"82","author":"Adachi","year":"2014","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2024042910113337200_lvae041-B129","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JME-17-0035","article-title":"Somatic and inherited mutations in primary aldosteronism","volume":"59","author":"Fernandes-Rosa","year":"2017","journal-title":"J Mol Endocrinol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae041\/57150404\/lvae041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/4\/G1\/57305999\/lvae041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/4\/G1\/57305999\/lvae041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T10:13:29Z","timestamp":1714385609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/4\/G1\/7640153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae041","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,30]]}}}